Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. develops precision nerve-targeted medical device technology for diagnosing and treating diseases involving the nervous system. The company’s platform includes a catheter-based microchip sensing array intended to detect and differentiate neural signals and support transvascular approaches to peripheral nerve identification and treatment.
Recurring AMIX news centers on clinical and scientific updates for transvascular radiofrequency energy-based ablation, including pain mitigation research in pancreatic adenocarcinoma and peripheral nerve modulation. Company announcements also cover medical and interventional conference presentations, abstract selections, publication strategy, corporate presentations, and the clinical validation process for its minimally invasive nerve-targeted platform.
Autonomix Medical (NASDAQ: AMIX) released a new CEO Corner segment on Feb 25, 2026 featuring President and CEO Brad Hauser discussing the company’s publication strategy and efforts to expand scientific publications and presentations over the past 12–18 months.
Hauser emphasizes submitting clinical and technical data to competitive, peer-reviewed forums to validate Autonomix’s technology, build clinical credibility, and support long-term growth; the segment is available on the CEO Corner of the company website and social channels.
Autonomix Medical (NASDAQ: AMIX) announced that Clarke Wilkirson, PhD, will present new long-term clinical data on pain mitigation in pancreatic adenocarcinoma at the SSO 2026 Annual Meeting March 5-7 in Phoenix.
The oral podium presentation describes a long-term analysis of denervation using a minimally invasive transvascular RF energy-based ablation and its potential effects on pain control and quality of life.
Autonomix Medical (NASDAQ: AMIX) will present final clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the SIO 2026 Annual Scientific Meeting in Savannah, GA (Feb 4-8, 2026).
The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Feb 6, 2026, 5:30–6:30 PM EST, including a 10-minute talk and 5-minute discussion during the Science and Sips reception.
Autonomix (NASDAQ: AMIX) presented post hoc subgroup data from its Proof-of-Concept 1 study at the 2026 ASCO GI symposium showing rapid, durable pain relief for pancreatic cancer patients across Stage 2–4 disease.
Key findings: responding patients showed marked pain reduction within 24 hours; at 7 days, 93.75% (N=16) improved from severe to mild/moderate pain; at 4–6 weeks about two-thirds (N=9) maintained mild/elimination pain; at 3 months no responding patients (N=6) reported severe pain and 50% maintained mild/elimination levels. The analysis included three patients with unknown stage and noted limited longer-term follow-up in some due to disease progression.
Autonomix Medical (NASDAQ: AMIX) announced the European Patent Office granted EP4230133 on Dec 30, 2025 for “Controlled and Precise Treatment of Cardiac Tissues.”
The patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver closed-loop, feedback-driven neuromodulation, denervation, and/or ablation to precisely treat cardiac tissues. The grant complements U.S. Patent No. 12,369,852 and sits alongside the company’s stated IP portfolio of over 80 issued patents and 39 pending applications. The release highlights potential applications across arrhythmias, heart failure, hypertension (including renal–cardiac nerve interplay), ischemia/angina, and plaque/inflammation modulation.
Autonomix Medical (NASDAQ: AMIX) participated in a Virtual Investor CEO Connect segment on Dec 23, 2025. CEO Brad Hauser outlined two strategic priorities:
- Strengthening intellectual property to protect and expand the company’s platform.
- Evaluating multi‑indication opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary, and interventional pain management.
The CEO segment is available online for investors to review.
Autonomix Medical (NASDAQ: AMIX) announced its abstract was accepted for a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, January 8-10, 2026.
The poster, titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation," is Abstract 693 and will be presented by Robert S. Schwartz, MD, Chief Medical Officer. Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Presentation times: January 9, 2026, 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST.
Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.
In the segment, President and CEO Brad Hauser discussed two priorities: protecting the company’s platform via intellectual property, and exploring expansion beyond its initial pancreatic cancer focus into potential cardiovascular, pulmonary, and chronic pain targets.
The segment is available on the company website for investors and stakeholders seeking management commentary on strategy and pipeline direction.
Autonomix Medical (NASDAQ: AMIX) announced a private placement priced at the market under Nasdaq rules to a single institutional investor expected to close on or about November 19, 2025. The investor will purchase 4,501,666 shares of common stock (or pre-funded warrants) plus unregistered Series C warrants to buy up to 9,003,332 additional shares.
The combined effective offering price per share (with accompanying warrant) is $1.1107. Series C warrants carry an exercise price of $0.8607, are exercisable immediately, and expire 5.5 years after issuance. Gross proceeds are estimated at approximately $5.0 million before placement agent fees and expenses. Maxim Group is sole placement agent. The company will file a resale registration statement for the securities.
Autonomix Medical (NASDAQ: AMIX) announced a post-hoc subgroup analysis of its first-in-human PoC 1 study reporting sustained, clinically meaningful quality-of-life gains after targeted transvascular nerve ablation for severe pancreatic cancer pain.
Key numeric findings: symptom scores improved 14.53 points at 4–6 weeks (n=9) and 26.07 points at 3 months (n=6); functionality rose 8.15 and 25.56 points; global QOL improved 8.33 and 18.06 points. Stage 4/metastatic subgroup exceeded EORTC ≥10-point meaningful-change thresholds at multiple timepoints.
The company said results will inform its multicenter U.S. clinical trial planned to start in 2026.